discontinued
No description yet: the sentence for this tag has not been written. 1 record carries it: 1 target.
1 records
| Cancers | Other tags | ||||
|---|---|---|---|---|---|
LIV-1 (SLC39A6) SLC39A6 LIV-1 is an oestrogen-regulated zinc transporter on most breast cancers; the ADC against it (ladiratuzumab vedotin) showed activity in triple-negative disease but was discontinued in 2024. | Triple-negative breast cancer, HR-positive / HER2-negative breast cancer, Prostate cancer | none | none |